Dermapharm focuses on Wobenzym integration, SDAX shares on analysts’ radar
23.06.2026 - 10:02:22 | ad-hoc-news.de
By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-23, 09:59.
Dermapharm Holding (DE000A2GS5D8) stays in focus on Xetra as investors assess the integration of the recently acquired Wobenzym portfolio and its impact on earnings quality. The SDAX-listed pharmaceutical group draws continued interest from analysts who emphasize margin resilience in a competitive German generics and prescription drug market.
What recent reports highlight
Dermapharm has pushed its expansion strategy in recent quarters with bolt-on deals, including the acquisition of the enzyme preparation brand Wobenzym, which is intended to strengthen the portfolio of branded pharmaceuticals in Europe. According to a recent market report, the transaction underlines the company’s ambition to expand its self-pay and OTC footprint in the DACH region and selected international markets.A June 2026 report on the Wobenzym acquisition
Beyond M&A, Dermapharm continues to invest in production sites and supply-chain reliability for its generics and branded products, aiming to secure delivery capability to pharmacies and hospitals in Germany and neighboring countries. The company operates with a vertically integrated setup from development through production to distribution, which is meant to stabilize gross margins in an environment of price pressure from statutory health insurers.
Analysts’ view on margins and growth
Analyst platforms tracking Dermapharm report a broadly constructive stance on the shares, with a majority of covered research houses rating the stock at Buy or Overweight and only a minority on Hold.MarketScreener consensus data for Dermapharm Consensus expectations point to continued revenue growth in the low- to mid-single-digit percentage range over the coming years, supported by new product launches and portfolio expansion in dermatology, vitamins and nutraceuticals.
EBITDA margins for Dermapharm are expected by analysts to remain robust compared with several European peers in the generic and specialty pharma space, thanks to the relatively high share of proprietary and branded products. In sector comparisons, reference is often made to companies such as Pharma Mar or Sinopharm when discussing broader pharmaceutical valuations in Europe and Asia, although Dermapharm’s business mix is more focused on prescription dermatology, allergy treatments and self-medication products.A sector-focused analysis of Dermapharm and peers
All news and analysis on the Dermapharm shares
Further reporting on Dermapharm’s financial figures, M&A strategy and SDAX trading activity can be found in the dedicated topic overview.
The products behind the earnings
Dermapharm generates a major share of its revenues with prescription and OTC brands in dermatology, allergy and pain treatment, as well as vitamins and nutraceuticals sold in pharmacies. A prominent example in the expanded portfolio is Wobenzym, an established enzyme preparation used to support recovery in inflammatory and degenerative conditions, which the group has taken over to strengthen its branded self-medication offering in Europe.
Where the shares trade today
The Dermapharm shares (DE000A2GS5D8) trade on Xetra at 46.55 euros as of 2026-06-23, 09:30, placing the company in the mid-cap range of the SDAX segment on the German market.
Key data on the Dermapharm shares
- Company: Dermapharm Holding SE
- ISIN: DE000A2GS5D8
- WKN: A2GS5D
- Ticker: DMP
- Trading venue: Xetra
- Price (as of 2026-06-23, 09:30): 46.55 EUR
- Market cap: 2.45 billion EUR (as of 2026-06-23)
- Sector / industry: Pharmaceuticals / Biotechnology
- Index membership: SDAX
- Next earnings date: 2026-08-29
Disclaimer: This article is for informational purposes only and does not constitute investment advice, a recommendation to buy or sell securities, or any other form of financial service. All data have been compiled with care but without any claim to completeness or accuracy. Investors should conduct their own research and, where appropriate, consult a licensed financial advisor.
